Skip to main content

Table 4 Treatment with intravenous immunoglobulins and clinical outcomes

From: The importance of intravenous immunoglobulin treatment in critically ill patients with necrotizing soft tissue infection: a retrospective cohort study

Clinical outcomes

Adjusted HR/SHRa (95% CI)

In-hospital death

2.20 (0.24 to 20.2)

ICU length of stay

0.90 (0.41 to 1.98)

Acute renal failure

2.86 (1.33 to 6.15)

ARDS

1.20 (0.36 to 4.03)

Septic shock

1.86 (1.02 to 3.40)

  1. ICU, intensive care unit; ARDS, acute respiratory distress syndrome; HR, hazard ratio; SHR, subhazard ratio; CI, confidence interval
  2. aFor death a Cox regression model was used, resulting in a hazard ratio (HR) as estimate of effect, while for all other clinical outcomes the use of a competing risk regression model according to Fine and Gray resulted in subhazard ratios (SHR). All analyses were adjusted for age, sex, affected body surface area and simplified acute physiology score (SAPS) II at admission. Values < 1 correspond with a lower risk of the outcome in patients treated with intravenous immunoglobulins
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us